The toughest topics in cancer care will be on tap November 13-14, 2014, in Baltimore, Maryland, when AJMCLive presents Patient-Centered Oncology Care. If you've followed the discussion among pharmaceutical leaders, oncologists, and payers over access to care, you'll want to join stakeholders to discuss how to ensure patients get what they need while controlling costs.
From Diagnostics to Cancer Drug Costs, Nothing's Off Limits at AJMCLive's Patient Centered Oncology Care
FOR IMMEDIATE RELEASEOctober 28, 2014
PLAINSBORO, N.J. — Did you see Peter Bach, MD, discussing the high cost of cancer treatment on 60 Minutes recently? Did you read about the Institute of Medicine report, Dying in America, on the widespread failure of the US healthcare system to deliver good end-of-life care?
Have you followed the growing debate between payers and pharmaceutical manufacturers over which one deserves blame when patients can’t get access to the best cancer drugs?
If you have, then you don’t want to miss “Patient-Centered Oncology Care,” the third annual multistakeholder gathering from AJMCLive, the meeting series of The American Journal of Managed Care. This year’s timely lineup, promises to be the best yet, and includes:
“If there is an important topic in cancer care today, it will be aired at this meeting,” said Brian Haug, president of Managed Markets and the meeting’s host. “We are creating opportunities for everyone involved in cancer care to meet in one place, to have the dialogue that is so important to making care better for patients.”
The conference will feature representation from major national payers, sessions on accountable care organizations and patient-centered medical homes, emerging national quality standards, and more. For a full agenda, faculty lineup, and registration, visit http://www.ajmc.com/meetings/pcoc14.
The conference will take place at the Baltimore Marriott Waterfront Hotel, 700 Aliceanna St.,
Baltimore, Maryland, 21202. Hotel phone is (410) 385-3000. For staff with AJMCLive, call (609) 716-7777, x 131 or 124.
About the Journal
The American Journal of Managed Care, now in its 20th year of publication, is the leading peer-reviewed journal dedicated to issues in managed care. Other titles in the AJMC family of publications are The American Journal of Pharmacy Benefits, which provides pharmacy and formulary decision makers with information to improve the efficiency and health outcomes in managing pharmaceutical care. In December 2013, AJMC introduced The American Journal of Accountable Care, which publishes research and commentary devoted to understanding changes to the healthcare system due to the 2010 Affordable Care Act. AJMC’s news publications, the Evidence-Based series, bring together stakeholder views from payers, providers, policymakers and pharmaceutical leaders in the areas of oncology, diabetes management, and immunology and infectious disease. To order reprints of articles appearing in AJMC publications, please call (609) 716-7777, x 131.
CONTACT: Nicole Beagin (609) 716-7777 x 131
Health Care Utilization and Cost of Diagnostic Testing for Respiratory Infections
September 17th 2025Syndromic reverse transcriptase–polymerase chain reaction tests for respiratory infections were associated with lower health care resource utilization and costs, implicating potential for improved value in patient care.
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More